FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 42-44

  Bermúdez, Arancha ^a   Pérez Vázquez, German ^a   Insunza, Andres ^a   Baro, Julio ^a   Colorado, Mercedes ^a   Conde, Eulogio ^a   Díez Gallarreta, Zuriñe ^a   Gutiérrez, Maria Luisa ^b   López Duarte, Monica ^a   Olalla, Ignacio ^b   Sanroma, Pedro ^a   Yañez, Lucrecia ^a   Iriondo, Arturo ^a   Richard, Carlos ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; LEVOFLOXACIN; POSACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMORBIDITY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; KARYOTYPE; LEUKAPHERESIS; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 84155162601     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22192     Document Type: Article

References (24)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-1915.
3. Luger SM. Treating the elderly patient with acute myelogenous leukemia. Hematology Am Soc Haematol Educ Program 2010; 62-69.
4. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179-4187.
5. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109: 1376-1383.
6. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116: 4422-4429.
7. Röllig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116: 971-978.
8. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008.
9. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
10. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117: 1828-1833.
11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
12. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109: 1387-1394.
13. Schiller GJ, O'Brien SM, Pigneux A, et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol 2010; 28: 815-821.
14. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavourable prognostic factors. J Clin Oncol 2010; 28: 549-555.
15. Juliusson G, Billström R, Gruber A, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 2006; 20: 42-47.
16. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemias 2004; 18: 809-816.
17. Schiffer CA."I am older, not elderly, " said the patient with acute myeloid leukemia. J Clin Oncol 2010; 28: 521-522.
18. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 513-520.
19. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939-944.
20. Rubia de la J, Regadera AI, Martín G, et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Res 2002; 26: 725-730.
21. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003; 82: 231-235.
22. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
23. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
24. Pollyea D, Kohrt HE, Medeiros Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011; 152: 524-542